Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04024371
Other study ID # RTOC1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 16, 2019
Est. completion date February 1, 2021

Study information

Verified date July 2022
Source Maastricht University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Deficits or abnormalities in reward processing are present in a number of psychiatric disorders. The overarching objective of the study is to conduct initial validation work towards optimising three experimental tasks - which have previously been shown to be sensitive to reward processing deficits - for future use in clinical trials. This initial validation work has the primary objective to uncover group differences in task outcome measures between healthy control participants, participants with Major Depressive Disorder (MDD) and participants with schizophrenia (SZ) using statistical analyses. This may provide some indications for the use of these tasks as clinically-relevant biomarkers. Primary aims include: (i) comparing the investigator's endpoint means and distributions to those in previously published data; (ii) replication of previously-reported differences between MDD/SZ vs. healthy control participants, and, (iii) exploring the relationship between task endpoints and subjective participant- and clinician-rated report of reward-related constructs (e.g. anhedonia, negative symptoms).


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date February 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 55 Years
Eligibility General: 1. Be able to provide signed and dated informed consent for study participation. 2. Be male or female, aged between 20 and 55 years, inclusive. 3. Be able to read, write, and speak the language in which psychometric tests are provided, with acceptable visual and auditory acuity (corrected if necessary). 4. Unless otherwise stated, CNS medications to treat symptoms of MDD or SZ and other stable CNS conditions requiring medication is permitted in the MDD and SZ groups, provided the daily dose of medication has not been changed by more than +/- 30% in the last 4 weeks before the start of the study, and is not expected to change by a larger fraction while participating in the study. MDD Participants must: 1. Have a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD, confirmed by the result of the MINI interview conducted by the site at screening. Subjects with a diagnosis of comorbid Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific phobia may be included. 2. Meet the DSM-5 criteria for a current Major Depressive Episode, with the current depressive episode not having lasted longer than 6 months. 3. If undergoing treatment, be currently treated with an antidepressant approved in this protocol for at least 4 continuous weeks. Psychological treatments (e.g., Cognitive Behaviour Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy etc.) are all permitted in this study regardless of frequency and duration. SZ Subjects must: 1. Have a primary diagnosis of schizophrenia according to the Statistical Manual of Mental Disorders 5th edition (DSM-5), confirmed by the result of the MINI interview conducted by the site at screening. Subjects with a diagnosis of comorbid Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific phobia may be included. 2. Dose of antipsychotics not exceeding the equivalent of 6 mg risperidone.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-rating Questionnaires
Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995) Quick Inventory of Depressive Symptomatology (QIDS; 16 items) Behavioral avoidance/inhibition Scales (BIS/BAS)
Measures of Reward processing/reinforcement learning
Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG) Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG) Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)
Additional Schizophrenia-specific Questionnaires and Interviews
Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987) Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)

Locations

Country Name City State
Germany University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherap Frankfurt
Greece Aristotle University of Thessaloniki, School of Medicine, Department of Clinical Pharmacology Thessaloníki
Netherlands Maastricht University Maastricht
Spain Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona Barcelona

Sponsors (7)

Lead Sponsor Collaborator
Maastricht University Aristotle University Of Thessaloniki, Biotrial, Maastricht University, School for Mental Health and Neuroscience, P1vital Products LTD., The Institute of Neuropsychiatry and Addictions (INAD), Parc de Salut Mar, Barcelona, University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy

Countries where clinical trial is conducted

Germany,  Greece,  Netherlands,  Spain, 

References & Publications (3)

Collins AGE, Albrecht MA, Waltz JA, Gold JM, Frank MJ. Interactions Among Working Memory, Reinforcement Learning, and Effort in Value-Based Choice: A New Paradigm and Selective Deficits in Schizophrenia. Biol Psychiatry. 2017 Sep 15;82(6):431-439. doi: 10.1016/j.biopsych.2017.05.017. Epub 2017 May 31. — View Citation

Foti D, Hajcak G. Depression and reduced sensitivity to non-rewards versus rewards: Evidence from event-related potentials. Biol Psychol. 2009 Apr;81(1):1-8. doi: 10.1016/j.biopsycho.2008.12.004. Epub 2008 Dec 31. — View Citation

Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1-Psychometric Characteristics of 5 Paradigms — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Grip effort outcome Percentage of hard task choices at different reward levels Day 1
Primary Doors task outcome "Feedback negativity", an event-related potential (ERP) at approximately 300ms after feedback presentation indicating a favourable versus unfavourable outcome in paradigms in which the participant loses or wins money. Day 1
Primary RL/WM task outcome Accuracy as function of set size (difficulty) Day 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A